AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01366560
Drug: Active
RxNorm normalized name: Active
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GSK962040 125mg
Trial: NCT00332033
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01313936
Drug: Metaiodobenzylguanidine (MIBG)
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
Trial: NCT00237874
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000507
Drug: streptokinase
RxNorm normalized name: Streptokinase
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00170053
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
Trial: NCT02504008
Drug: AXS-02 (oral zoledronate)
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once weekly for 6 weeks
Trial: NCT03973840
Drug: Testosterone Undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose was given orally and allowed to reach steady state
Trial: NCT01745094
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01745094
Drug: solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03645876
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg
Trial: NCT03645876
Drug: BP102
RxNorm normalized name: Buprenorphine/Naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7.5mg/kg
Trial: NCT03645876
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130mg/m2
Trial: NCT01861990
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants enrolled on valproic acid arm.
Trial: NCT02550548
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
Trial: NCT02550548
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
Trial: NCT00000136
Drug: Foscarnet
RxNorm normalized name: Foscarnet
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg every 8 hours, 90 mg/kg/day
Trial: NCT00000136
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/kg every 12 hours, 5 mg/kg every 24 hours
Trial: NCT01505049
Drug: quadrivalent HPV vaccine
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
Trial: NCT00514150
Drug: Sodium Bicarbonate plus normal saline 0.9%
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
Trial: NCT01835067
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
Trial: NCT01835067
Drug: tPA
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of 50 micrograms tPA in 0.05 mls
Trial: NCT03506841
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
Trial: NCT00022620
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02320149
Drug: Sarecycline
RxNorm normalized name: SARECYCLINE
DrugBank: Sarecycline (DB12035)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg/day taken orally at the same time each day,
Trial: NCT00560079
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 600mg/day bid for 28 days
Trial: NCT00560079
Drug: Dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole 200mg/day bid for 28 days
Trial: NCT01658358
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily
Trial: NCT00190996
Drug: Duloxetine Hydrochloride
RxNorm normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01658358
Drug: Lipo-Dox
RxNorm normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
Trial: NCT03593707
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin
Trial: NCT03593707
Drug: PF-06865571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06865571
Trial: NCT00539331
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion
Trial: NCT00539331
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous injection
Trial: NCT03210376
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg/Kg, intravenously as a single bolus injection after surgery.
Trial: NCT03210376
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
Trial: NCT03695107
Drug: Nifedipine controlled released tablets
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lower blood pressure
Trial: NCT02812147
Drug: L-DOPS
RxNorm normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Added as described in the Arm/Group Descriptions.
Trial: NCT01690260
Drug: Bone Morphogenetic Protein 2
RxNorm normalized name: Bone morphogenetic protein 2
DrugBank: Dibotermin alfa (DB11639)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
Trial: NCT00914524
Drug: olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil tablets, once daily
Trial: NCT00000233
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00229632
Drug: Idebenone
RxNorm normalized name: Idebenone
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
Trial: NCT00908180
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02348606
Drug: JZP-110
RxNorm normalized name: JZP-386 free base
DrugBank: JZP-386 free base (DB17068)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00908180
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00908180
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00908180
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00908180
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03296930
Drug: Sofosbuvir 400 MG Oral Tablet,
RxNorm normalized name: SOFOSBUVIR 400 mg ORAL TABLET, FILM COATED [Sovaldi]
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Interferon free direct acting antiviral drugs used for treatment of HCV.
Trial: NCT03296930
Drug: Ombitasvir/paritaprevir/ritonavir
RxNorm normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Interferon free direct acting antiviral drugs used for treatment of HCV.
Trial: NCT01083329
Drug: nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Obese subjects will receive nicotinic acid or placebo for 16 weeks
Trial: NCT02571530
Drug: Intra-arterial Cerebral Infusion of Trastuzumab
RxNorm normalized name: methotrexate
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03980522
Drug: KPL-914
RxNorm normalized name: Immunoglobulin G4 [222-proline], anti-(human CD40 antigen) (human-Mus musculus monoclonal KPL-404 γ4-chain), disulfide with human-Mus musculus monoclonal KPL-404 κ-chain, dimer
DrugBank: Abiprubart (DB19333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to \<18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks.
Trial: NCT01675973
Drug: RANEXA
RxNorm normalized name: Ranexa
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg BID up to 1000mg BID
Trial: NCT01840501
Drug: JNJ-42721458 (single dose)
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
Trial: NCT01840501
Drug: JNJ-42721458 (multiple doses)
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
Trial: NCT01426373
Drug: Deoxycholic acid injection
RxNorm normalized name: deoxycholic acid Injection
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Trial: NCT01285310
Drug: Apremilast 30 mg
RxNorm normalized name: apremilast 30 MG
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
Trial: NCT01285310
Drug: Apremilast 20 mg
RxNorm normalized name: apremilast 20 MG
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
Trial: NCT04208620
Drug: Cotadutide
RxNorm normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide administered subcutaneously
Trial: NCT03107325
Drug: F-18 Fluorodeoxyglucose
RxNorm normalized name: Fludeoxyglucose F-18
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be asked to be imaged at an additional time point during an FDG PET study
Trial: NCT00555321
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
Trial: NCT00555321
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV), 20 mg, Day1 and Day 5
Trial: NCT00555321
Drug: Belatacept More Intensive (MI)
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])
Trial: NCT00555321
Drug: Belatacept Less Intensive (LI)
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)
Trial: NCT00555321
Drug: Mycophenolate Mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
Trial: NCT04440358
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
Trial: NCT01268839
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600mg tablet once daily for 14 days
Trial: NCT00722436
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/kg load, then 10 mg/kg/hr
Trial: NCT00722436
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04491838
Drug: Pozelimab
RxNorm normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous (SC) injection
Trial: NCT00236886
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04260035
Drug: Vasoactive Intestinal Polypeptide (VIP)
RxNorm normalized name: Vasoactive intestinal polypeptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
Trial: NCT01236495
Drug: spinal morphine 0.3 mg
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spinal morphine 0.3 mg
Trial: NCT01236495
Drug: spinal morphine 0.2 mg
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spinal morphine 0.2 mg
Trial: NCT01285505
Drug: alprazolam commercial sublingual formulation
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablet, single dose
Trial: NCT01285505
Drug: alprazolam test sublingual tablet
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablet, single dose
Trial: NCT00083772
Drug: Nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
Trial: NCT01456260
Drug: TAK-438
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
Trial: NCT01456260
Drug: TAK-438
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
Trial: NCT01456260
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
Trial: NCT01206439
Drug: nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nebivolol 5 or 10 mg oral, daily
Trial: NCT03417739
Drug: BVD-523
RxNorm normalized name: BVdU
DrugBank: Brivudine (DB03312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERK1 and ERK2 inhibitor
Trial: NCT03976934
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of tamsulosin tablets
Trial: NCT02242734
Drug: 20 mg HC-ER
RxNorm normalized name: Casporyn HC
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1-72 hours
Trial: NCT01055886
Drug: nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine patch, 7-21 mg.
Trial: NCT00779441
Drug: Zolpidem 10mg tablets
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00355524
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
Trial: NCT00725764
Drug: GSK1363089 (foretinib)
RxNorm normalized name: Foretinib
DrugBank: Foretinib (DB12307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multitargeted tyrosine kinase inhibitor
Trial: NCT00505531
Drug: Tramadol Extended Release Oral Capsule
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER- up to either 200 mg or 300 mg based on randomization
Trial: NCT00869115
Drug: Istaroxime
RxNorm normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
Trial: NCT00869115
Drug: Istaroxime
RxNorm normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
Trial: NCT00869115
Drug: Istaroxime
RxNorm normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
Trial: NCT00869115
Drug: Istaroxime
RxNorm normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo continuous i.v. infusion for 24 hours
Trial: NCT00505531
Drug: Benadryl
RxNorm normalized name: Benadryl
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo group will take up to 25 mg of Benadryl
Trial: NCT02625337
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02625337
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes